Effects of esomeprazole treatment for gastroesophageal reflux disease on quality of life in 12- to 17-year-old adolescents: an international health outcomes study

Thirumazhisai Gunasekaran, Vasundhara Tolia, Richard B Colletti, Benjamin D Gold, Barry Traxler, Marta Illueca, Joseph A Crawley, Thirumazhisai Gunasekaran, Vasundhara Tolia, Richard B Colletti, Benjamin D Gold, Barry Traxler, Marta Illueca, Joseph A Crawley

Abstract

Background: Although gastroesophageal reflux disease (GERD) is common in adolescents, the burden of GERD on health-related quality of life (HRQOL) in adolescents has not been previously evaluated. Therefore, the objective of the study was to examine the effect of GERD on HRQOL in adolescents.

Methods: This international, 31-site, 8-week safety study randomized adolescents, aged 12 to 17 years inclusive, with GERD to receive esomeprazole 20 or 40 mg once daily. The Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD), previously validated in adults, consists of 25 questions grouped into 5 domains: emotional distress, sleep disturbance, food/drink problems, physical/social functioning, and vitality. The QOLRAD was administered at the baseline and week-8 (final) visits.

Results: Of the 149 patients randomized, 134 completed the QOLRAD at baseline and final visits and were eligible for analysis of their HRQOL data. Baseline QOLRAD scores indicated GERD had a negative effect on the HRQOL of these adolescents, especially in the domains of vitality and emotional distress, and problems with food/drink. At the final visit, mean scores for all 5 QOLRAD domains improved significantly (P < .0001); change of scores (ie, delta) for all domains met or exceeded the adult QOLRAD minimal clinically significant difference standard of 0.5 units.

Conclusion: GERD had a negative effect on QOL in adolescents. After esomeprazole treatment, statistically and clinically significant improvements occurred in all domains of the QOLRAD for these adolescents.

Trial registration: D9614C00098; ClinicalTrials.gov Identifier NCT00241501.

Figures

Figure 1
Figure 1
Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD) mean total scores. QOLRAD mean total scores ± standard deviation at baseline and final visit (both based on a 1-week recall) (n = 134). Higher scores indicate better quality of life. aP < .001 vs baseline.
Figure 2
Figure 2
Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD) mean domain scores. QOLRAD mean domain scores ± standard deviation at baseline and final visit (both based on a 1-week recall) (n = 134). Higher scores indicate better quality of life. aP < .001 vs baseline.

References

    1. Gold BD, Freston JW. Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment. Pediatr Drugs. 2002;4:673–685.
    1. Ramesh P, Santiago M, Schmidt K, Gunasekaran TS. Prevalence of gastroesophageal reflux disease (GERD) symptoms in an African American (AA) predominant adolescent high school population [abstract] J Pediatr Gastroenterol Nutr. 2001;33:421.
    1. Gunasekaran TS, Dahlberg M, Ramesh P, Namachivayam G. Prevalence and associated features of gastroesophageal reflux symptoms in a Caucasianpredominant adolescent school population. Dig Dis Sci. 2008;53:2373–2379. doi: 10.1007/s10620-007-0150-5.
    1. Asokan S, Ramesh P, Gunasekaran TS, Creech S. Prevalence of gastroesophageal reflux disease (GERD) symptoms in a Hispanic American adolescent [abstract] J Pediatr Gastroenterol Nutr. 2003;37:337.
    1. Nelson SP, Chen EH, Syniar GM, Christoffel KK. for Pediatric Practice Research Group. Prevalence of symptoms of gastroesophageal reflux during childhood. Arch Pediatr Adolesc Med. 2000;154:150–154.
    1. Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis. 2004;22:108–114. doi: 10.1159/000080308.
    1. Havelund T, Lind T, Wiklund I, Glise H, Hernqvist H, Lauritsen K, Lundell L, Pedersen SA, Carlsson R, Junghard O, Stubberöd A, Anker-Hansen O. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol. 1999;94:1782–1789. doi: 10.1111/j.1572-0241.1999.01206.x.
    1. Revicki DA, Crawley JA, Zodet MW, Levine DS, Joelsson BO. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastrooesophageal reflux disease. Aliment Pharmacol Ther. 1999;13:1621–1630. doi: 10.1046/j.1365-2036.1999.00669.x.
    1. Talley NJ, Fullerton S, Junghard O, Wiklund I. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol. 2001;96:1998–2004. doi: 10.1111/j.1572-0241.2001.03932.x.
    1. De La Loge C, Trudeau E, Marquis P, Revicki DA, Rentz AM, Stanghellini V, Talley NJ, Kahrilas P, Tack J, Dubois D. Responsiveness and interpretation of a quality of life questionnaire specific to upper gastrointestinal disorders. Clin Gastroenterol Hepatol. 2004;2:778–786. doi: 10.1016/S1542-3565(04)00349-0.
    1. Pace F, Negrini C, Wiklund I, Rossi C, Savarino V. for The Italian One Investigators Study Group. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;22:349–356. doi: 10.1111/j.1365-2036.2005.02558.x.
    1. Madisch A, Kulich KR, Malfertheiner P, Ziegler K, Bayerdörffer E, Miehlke S, Labenz J, Carlsson J, Wiklund IK. Impact of reflux disease on general and disease-related quality of life--evidence from a recent comparative methodological study in Germany. Z Gastroenterol. 2003;41:1137–1143. doi: 10.1055/s-2003-45277.
    1. Hansen ÅN, Bergheim R, Fagertun H, Lund H, Wiklund I, Moum B. Long-term management of patients with symptoms of gastro-oesophageal reflux disease--a Norwegian randomized prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting. Int J Clin Pract. 2006;60:15–22. doi: 10.1111/j.1368-5031.2006.00768.x.
    1. El-Dika S, Guyatt GH, Armstrong D, Degl'innocenti A, Wiklund I, Fallone CA, Tanser L, Veldhuyzen van Zanten S, Heels-Ansdell D, Wahlqvist P, Chiba N, Barkun AN, Austin P, Schünemann HJ. The impact of illness in patients with moderate to severe gastro-esophageal reflux disease. BMC Gastroenterol. 2005;5:23–30. doi: 10.1186/1471-230X-5-23.
    1. Tolia V, Essenbacher L, Boyer K, Ager J. Gastroesophageal reflux disease (GERD) questionnaire to assess quality of life (QOL) in patients and parents [abstract: poster session] J Pediatr Gastroenterol Nutr. 2004;39:S424–S425.
    1. Wiklund IK, Junghard O, Grace E, Talley NJ, Kamm M, Veldhuyzen van Zanten S, Paré P, Chiba N, Leddin DS, Bigard MA, Colin R, Schoenfeld P. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD) Eur J Surg Suppl. 1998;583:41–49.
    1. Rudolph CD, Mazur LJ, Liptak GS, Baker RD, Boyle JT, Colletti RB, Gerson WT, Werlin SL. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr. 2001;32(suppl 2):S1–S31. doi: 10.1097/00005176-200100002-00001.
    1. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190–200. doi: 10.1111/j.1572-0241.2005.41217.x.
    1. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, Marino V, Hamelin B, Levine JG. for Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96:656–665. doi: 10.1111/j.1572-0241.2001.03600.x.
    1. Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J, Damico D, Hamelin B. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol. 2001;96:27–34. doi: 10.1111/j.1572-0241.2001.03443.x.
    1. Fiedorek S, Tolia V, Gold BD, Huang B, Stolle J, Lee C, Gremse D. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2005;40:319–327. doi: 10.1097/01.MPG.0000155369.54464.41.
    1. Hassall E, Israel D, Shepherd R, Radke M, Dalväg A, Sköld B, Junghard O, Lundborg P. for International Pediatric Omeprazole Study Group. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. J Pediatr. 2000;137:800–807. doi: 10.1067/mpd.2000.109607.
    1. Gold BD, Gunasekaran T, Tolia V, Wetzler G, Conter H, Traxler B, Illueca M. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2007;45:520–529. doi: 10.1097/MPG.0b013e318148c17c.
    1. Kulich K, Wiklund I, Junghard O. Factor structure of the quality of life in reflux and dyspepsia (QOLRAD) questionnaire evaluated in patients with heartburn predominant reflux disease. Qual Life Res. 2003;12:699–708. doi: 10.1023/A:1025192100450.
    1. Junghard O, Wiklund IK. Effect of baseline symptom severity on patient-reported outcomes in gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2007;19:555–560. doi: 10.1097/MEG.0b013e328133f2d1.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe